Norberg B, Norberg A, Parkhede U, Gippert H
Eur J Clin Pharmacol. 1979 Jun 12;15(5):357-61. doi: 10.1007/BF00558440.
An evaluation has been made of the clinical and laboratory effects of short-term (34 days), high-dose (2g x 3 daily) treatment with methenamine hippurate (MH) of 14 geriatric patients with an indwelling catheter and clinical features of urinary tract infection. During MH treatment the number of catheter changes was halved, each catheter remaining in situ for an average of 12.0 days as compared to 6.2 days in the pre-treatment control period and 5.2 days in the post-treatment control period; the difference is significant (p = 0.008; Friedman two-way analysis of variance). Urine pH was reduced (pH 7.0--6.5--7.0; p = 0.01) and the standard bicarbonate in blood was slightly elevated (24.1--25.7--25.0 mmol/l; p= 0.008) during the MH treatment period, when compared to pre- and post-treatment control periods. It is suggested that MH treatment reduced the complications associated with indwelling catheters due to reduction in urine pH, bacteriuria, and pyuria. Blockage of catheters is thought to be due to intraluminal salt precipitations with trapping of clumps, and is primarily not correlated with urine viscosity.
对14例留置导尿管且有尿路感染临床特征的老年患者，采用高剂量（每日3次，每次2g）马尿酸乌洛托品（MH）进行短期（34天）治疗，评估其临床和实验室效果。在MH治疗期间，更换导尿管的次数减半，每个导尿管平均留置12.0天，而治疗前对照期为6.2天，治疗后对照期为5.2天；差异有统计学意义（p = 0.008；Friedman双向方差分析）。与治疗前和治疗后对照期相比，MH治疗期间尿液pH值降低（pH 7.0--6.5--7.0；p = 0.01），血液中标准碳酸氢盐略有升高（24.1--25.7--25.0 mmol/l；p = 0.008）。提示MH治疗可减少因尿液pH值降低、菌尿和脓尿导致的与留置导尿管相关的并发症。导尿管堵塞被认为是由于管腔内盐沉淀并困住团块所致，主要与尿液黏稠度无关。
